Research on Sareum Holdings Plc (SAR) from Edison
Sareum has announced plans for an equity fundraise to advance SDC-1801, its lead oral TYK2/JAK1 inhibitor, towards its next clinical inflection point. The company is using AIM's newly introduced Capital Access Window, voluntarily suspending trading from 8 October to facilitate broader investor part
View Full ResearchDisclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
